<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648270</url>
  </required_header>
  <id_info>
    <org_study_id>201202087</org_study_id>
    <nct_id>NCT01648270</nct_id>
  </id_info>
  <brief_title>Buprenorphine Disposition and Cyclosporine</brief_title>
  <official_title>Influence of Cyclosporine on Buprenorphine Disposition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The determine the effect of cyclosporine on buprenorphine disposition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects studied on four occasions:

        1. Intravenous buprenorphine

        2. Sublingual buprenorphine

        3. Cyclosporine, then intravenous buprenorphine. Subjects then take oral cyclosporine twice
           daily, until

        4. Sublingual buprenorphine; continue oral cyclosporine twice daily for 5 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Buprenorphine Plasma Cmax</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be studied on four occasions. Sessions and drugs are:
Intravenous buprenorphine
Sublingual buprenorphine
Cyclosporine plus intravenous buprenorphine
Cyclosporine plus sublingual buprenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine</intervention_name>
    <description>Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-50 yr old

          -  Good general health with no remarkable medical conditions

          -  BMI &lt; 33

          -  Provide informed consent

        Exclusion Criteria:

          -  Known history of liver or kidney disease

          -  Use of prescription or non prescription medications, herbals or foods known to be
             metabolized by or affecting CYP3A

          -  Females who are pregnant or nursing

          -  Known history of drug or alcohol addiction (prior or present addiction or treatment
             for addiction)

          -  Direct physical access to and routine handling of addicting drugs in the regular
             course of duty (a routine exclusion from studies of drugs with addiction potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Kharasch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <results_first_submitted>June 20, 2018</results_first_submitted>
  <results_first_submitted_qc>January 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>buprenorphine</keyword>
  <keyword>CYP3A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Subjects will be studied on four occasions. Sessions and drugs are:
Intravenous buprenorphine
Sublingual buprenorphine
Cyclosporine plus intravenous buprenorphine
Cyclosporine plus sublingual buprenorphine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intravenous Buprenorphine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Sublingual Buprenorphine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cyclosporine Plus IV Buprenorphine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cyclosporine + Sublingual Buprenorphine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Arm</title>
          <description>Subjects will be studied on four occasions. Sessions and drugs are:
Intravenous buprenorphine
Sublingual buprenorphine
Cyclosporine plus intravenous buprenorphine
Cyclosporine plus sublingual buprenorphine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Buprenorphine Plasma Cmax</title>
        <time_frame>96 hours</time_frame>
        <population>0 Participants Analyzed. The PI has left the institution. Sincere efforts were made to contact the PI but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Buprenorphine</title>
            <description>Intravenous buprenorphine: 0.2 mg infused over 1 hr</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Buprenorphine</title>
            <description>Sublingual buprenorphine: 2 mg</description>
          </group>
          <group group_id="O3">
            <title>Cyclosporine + IV Buprenorphine</title>
            <description>Cyclosporine (2.5mg/kg/hr infused over 2 hr), then intravenous buprenor-phine 0.2 mg infused over 1 hr beginning 1 hr after starting cyclosporine. Subjects then take oral cyclosporine 4.5 mg/kg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Cyclosporine + Sublingual Buprenorphine</title>
            <description>Sublingual buprenorphine: 2 mg; continue oral cyclosporine 4.5 mg/kg twice daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Buprenorphine Plasma Cmax</title>
          <population>0 Participants Analyzed. The PI has left the institution. Sincere efforts were made to contact the PI but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Buprenorphine</title>
          <description>Intravenous buprenorphine: 0.2 mg infused over 1 hr</description>
        </group>
        <group group_id="E2">
          <title>Sublingual Buprenorphine</title>
          <description>Sublingual buprenorphine: 2 mg</description>
        </group>
        <group group_id="E3">
          <title>Cyclosporine Plus Intravenous Buprenorphine</title>
          <description>Cyclosporine (2.5mg/kg/hr infused over 2 hr), then intravenous buprenor-phine 0.2 mg infused over 1 hr beginning 1 hr after starting cyclosporine. Subjects then take oral cyclosporine 4.5 mg/kg twice daily</description>
        </group>
        <group group_id="E4">
          <title>Cyclosporine Plus Sublingual Buprenorphine</title>
          <description>Sublingual buprenorphine: 2 mg; continue oral cyclosporine 4.5 mg/kg twice daily for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>itch</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizzyness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Evan Kharasch MD PhD</name_or_title>
      <organization>Washington University</organization>
      <phone>3143628796</phone>
      <email>kharasch@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

